Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.400
0.00 (0.00%)
At close: Apr 29, 2025, 4:00 PM
1.170
-0.230 (-16.43%)
After-hours: Apr 29, 2025, 4:56 PM EDT
Akari Therapeutics, Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Akari Therapeutics,.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Akari Therapeutics,.
Recommendation Trends
Rating | Jul '22 | Aug '22 | Sep '22 | Oct '22 | Nov '22 | Dec '22 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 0 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +2,042.86% | Dec 5, 2022 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +5,614.29% | Nov 1, 2022 |
B. Riley Securities | B. Riley Securities | Strong Buy Maintains $140 → $100 | Strong Buy | Maintains | $140 → $100 | +7,042.86% | Mar 13, 2020 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $300 → $160 | Strong Buy | Maintains | $300 → $160 | +11,328.57% | Mar 29, 2018 |
B. Riley Securities | B. Riley Securities | Hold Initiates $60 | Hold | Initiates | $60 | +4,185.71% | Feb 8, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.67
from -1.66
EPS Next Year
n/a
from -3.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 |
---|---|
High | 4.4M |
Avg | 4.3M |
Low | 4.1M |
Revenue Growth
Revenue Growth | 2025 |
---|---|
High | - |
Avg | - |
Low | - |
EPS Forecast
EPS | 2025 |
---|---|
High | -3.78 |
Avg | -3.67 |
Low | -3.53 |
EPS Growth
EPS Growth | 2025 |
---|---|
High | - |
Avg | - |
Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.